The stock has now surged more than 150% in the last two days as Wall Street is clearly excited about the prospects of the firm’s MIRASOL treatment after phase 3 data showed statistically significant results compared to chemotherapy in ovarian cancer patients who have received therapy.
MIRASOL showed a 33% reduction in death risk in the trial.
After more than doubling on this news, IMGN currently has a market cap of just over $3 billion. The technical outlook here is extremely positive, although a snap-back move in the coming days is possible due to the extended move in the name.
Featured photo by National Cancer Institute on Unsplash.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
